H
Hidefumi Higashi
Researcher at Memorial Hospital of South Bend
Publications - 91
Citations - 2531
Hidefumi Higashi is an academic researcher from Memorial Hospital of South Bend. The author has contributed to research in topics: Hepatectomy & Varices. The author has an hindex of 25, co-authored 90 publications receiving 2409 citations. Previous affiliations of Hidefumi Higashi include Kyushu University & University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Serum hyaluronic acid for the assessment of graft viability in porcine liver transplantation
Hidetoshi Itasaka,Keiji Kishikawa,Taketoshi Suehiro,Katsuhiko Yanaga,Mitsuo Shimada,Hidefumi Higashi,S Kakizoe,Tetsuo Ikeda,Shigeki Wakiyama,Keizo Sugimachi +9 more
TL;DR: The measurement of serum HA is a potentially effective index for evaluating hepatic allograft viability and demonstrated a significant correlation with prothrombin time, ß-glucuronidase, and aspartate aminotransferase at 120 min after reperfusion.
Journal ArticleDOI
Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer—LOGIK 0601 study
Tokujiro Yano,Koji Yamazaki,Riichiroh Maruyama,Shoji Tokunaga,Fumihiro Shoji,Hidefumi Higashi,Sadanori Takeo,Yukito Ichinose,Yoshihiko Maehara +8 more
TL;DR: Postoperative long-term administration of S-1 seems feasible as adjuvant chemotherapy for NSCLC, with few adverse events except for the early development of anorexia, especially in the elderly patients.
Journal Article
A prospective randomized trial of schedules for sclerosing esophageal varices. 1-versus 2-week intervals.
TL;DR: There were no significant differences between the 1-week and 2-week interval groups with regard to total number of sclerotherapy sessions, total volume of the sclerosant used (5% ethanolamine oleate) or rate of complications such as pyrexia, stricture and pleural effusion.
Journal ArticleDOI
Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)
Eiji Oki,Yasunori Emi,Yuji Miyamoto,Akira Kabashima,Hidefumi Higashi,Yutaka Ogata,Masahiko Ikebe,Hiroshi Saeki,Shoji Tokunaga,Ken Shirabe,Toru Beppu,Shinji Uchida,Mitsuhisa Takatsuki,Masahiko Sakoda,Susumu Eguchi,Yoshito Akagi,Yoshihiro Kakeji,Hideo Baba,Shoji Natsugoe,Yoshihiko Maehara +19 more
TL;DR: SOX plus cetuximab is safe and effective for advanced colorectal cancer with limited liver metastasis, and may lead to high liver resectability.
Journal ArticleDOI
Incidence and predictors of deep venous thrombosis after abdominal oncologic surgery: prospective Doppler ultrasound screening.
Keishi Sugimachi,Hirotada Tajiri,Nao Kinjo,Masahiko Ikebe,Huanlin Wang,Kiyoshi Tanaka,Junko Tanaka,Shuichi Tsukamoto,Shinsuke Mii,Hidefumi Higashi +9 more
TL;DR: DUS is noninvasive and is useful for postoperative DVT screening and thromboprophylaxis is essential in high-risk patients who have undergone abdominal oncologic surgery.